2OG8

crystal structure of aminoquinazoline 36 bound to Lck

Summary for 2OG8

• Entry DOI: 10.2210/pdb2og8/pdb
• Related: 2OFV
• Descriptor: Proto-oncogene tyrosine-protein kinase LCK, N-{2-[(N,N-DIETHYLGLYCYL)AMINO]-5-(TRIFLUOROMETHYL)PHENYL}-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6-YL]BENZAMIDE (3 entities in total)
• Functional Keywords: lck, kinase domain, transferase
• Biological source: Homo sapiens (human)
• Cellular location: Cytoplasm: P06239
• Total number of polymer chains: 2
• Total formula weight: 62163.11

Authors

Huang, X. (deposition date: 2007-01-05, release date: 2007-02-27, Last modification date: 2023-08-30)

Primary citation

DiMauro, E.F.,Newcomb, J.,Nunes, J.J.,Bemis, J.E.,Boucher, C.,Buchanan, J.L.,Buckner, W.H.,Cee, V.J.,Chai, L.,Deak, H.L.,Epstein, L.F.,Faust, T.,Gallant, P.,Geuns-Meyer, S.D.,Gore, A.,Gu, Y.,Henkle, B.,Hodous, B.L.,Hsieh, F.,Huang, X.,Kim, J.L.,Lee, J.H.,Martin, M.W.,Masse, C.E.,McGowan, D.C.,Metz, D.,Morgenstern, K.A.,Oliveira-dos-Santos, A.,Patel, V.F.,Powers, D.,Rose, P.E.,Schneider, S.,Tomlinson, S.A.,Tudor, Y.Y.,Turci, S.M.,Welcher, A.A.,White, R.D.,Zhao, H.,Zhu, L.,Zhu, X.
Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity
J.Med.Chem., 49:5671-5686, 2006

PubMed Abstract: The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Optimized, orally bioavailable compounds 32 and 47 exhibit anti-inflammatory activity (ED(50) of 22 and 11 mg/kg, respectively) in the anti-CD3-induced production of interleukin-2 (IL-2) in mice.

PubMed: 16970394
DOI: 10.1021/jm0605482

Experimental method

X-RAY DIFFRACTION (2.3 Å)